Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition (TRIAGE)
|ClinicalTrials.gov Identifier: NCT01582217|
Recruitment Status : Completed
First Posted : April 20, 2012
Last Update Posted : December 23, 2015
|Condition or disease|
|Percutaneous Coronary Intervention Dual Antiplatelet Therapy Aspirin Clopidogrel|
|Study Type :||Observational|
|Actual Enrollment :||318 participants|
|Official Title:||TRIAGE: Patients Undergoing Percutaneous Coronary Interventions to Improve Clinical Outcomes Through Optimal Platelet Inhibition|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
SA + 5mg prasugrel
Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
ASA + 10 mg prasugrel
Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
ASA + 75 mg clopidogrel daily
Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age >75; Wt< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
- MACE [ Time Frame: 12 months ]Major adverse cardiac events (all-cause death, myocardial infarction and stent thrombosis)
- Rates of major bleeding [ Time Frame: 12 months ]The rates of major bleeding in patients treated with a thienopyridine based on the clinical algorithm.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01582217
|United States, New York|
|Mount Sinai Medical Center|
|New York, New York, United States, 10029|
|Principal Investigator:||George Dangas, MD||Icahn School of Medicine at Mount Sinai|